BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the investigation of DX-2930 ...

“Why you can trust Digital Trends – We have a 20-year history of testing, reviewing, and rating products, services and apps to help you make a sound buying decision. Find out more about how we test ...

We’ve been rather taken with some of Acer’s recent laptops, especially the Blu-ray toting 6920G, so when we were offered the chance to preview its latest machine — based on Intel's brand-spanking-new ...

Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting Results Provide Important Clinical Proof-of-Concept, Dose Response and Safety ...